Lineage Cell Therapeutics, Inc. Common Stock (LCTX)
SG&A Expenses
$5.22M
Quarterly · Period ending: · USD
LCTX SG&A Expenses
Latest reported$5.22Mperiod ending
Latest reported$5.22Mperiod ending
LCTX Quarterly SG&A Expenses ($100.00K → $5.22M)
Quarterly SG&A Expenses
High-resolution chart · PNG
LCTX sg&a expenses history
Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | SG&A Expenses (USD) |
|---|---|
| 5,218,000 | |
| 5,084,000 | |
| 4,852,000 | |
| 4,191,000 | |
| 4,560,000 | |
| 4,857,000 | |
| 4,401,000 | |
| 4,410,000 | |
| 4,363,000 | |
| 4,844,000 | |
| 4,145,000 | |
| 4,041,000 | |
| 4,249,000 | |
| 4,724,000 | |
| 4,348,000 | |
| 4,422,000 | |
| 5,270,000 | |
| 8,469,000 | |
| 4,424,000 | |
| 5,317,000 | |
| 4,536,000 | |
| 3,935,000 | |
| 3,516,000 | |
| 3,628,000 | |
| 3,908,000 | |
| 4,519,000 | |
| 4,504,000 | |
| 4,609,000 | |
| 6,258,000 | |
| 8,660,000 | |
| 7,033,000 | |
| 6,422,000 | |
| 5,227,000 | |
| 6,044,000 | |
| 5,811,000 | |
| 4,587,000 | |
| 4,423,000 | |
| 5,101,000 | |
| 5,343,000 | |
| 4,574,000 | |
| 6,636,000 | |
| 11,872,000 | |
| 10,223,000 | |
| 7,545,000 | |
| 6,186,000 | |
| 5,178,800 | |
| 4,791,898 | |
| 4,261,450 | |
| 4,835,972 | |
| 3,667,171 | |
| 4,284,726 | |
| 4,267,875 | |
| 3,621,570 | |
| 3,416,145 | |
| 3,327,238 | |
| 2,234,905 | |
| 2,413,641 | |
| 2,368,705 | |
| 2,964,112 | |
| 1,929,711 | |
| 2,451,261 | |
| 1,994,847 | |
| 1,679,034 | |
| 1,464,631 | |
| 1,566,675 | |
| 933,298 | |
| -2,043,870 | |
| 2,637,133 | |
| 900,146 | |
| 682,174 | |
| 859,696 | |
| 792,306 | |
| 532,358 | |
| 435,939 | |
| 372,753 | |
| 216,443 | |
| 293,772 | |
| 417,780 | |
| 352,317 | |
| 301,924 | |
| 402,379 | |
| 436,881 | |
| 364,007 | |
| 242,988 | |
| 334,938 | |
| 454,000 | |
| 428,934 | |
| 280,712 | |
| 366,334 | |
| 408,392 | |
| 316,945 | |
| 227,432 | |
| 378,567 | |
| 337,768 | |
| 544,679 | |
| 151,446 | |
| 290,627 | |
| 331,407 | |
| 181,741 | |
| 734,024 |